Bioventus Inc. (NASDAQ:BVS) Receives Average Recommendation of “Buy” from Analysts

Bioventus Inc. (NASDAQ:BVS) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $14.20.

BVS has been the subject of several research analyst reports. Barrington Research reiterated an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research report on Friday, May 22nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research report on Tuesday. CJS Securities initiated coverage on Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective for the company. Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, Craig Hallum boosted their price objective on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th.

Hedge Funds Weigh In On Bioventus

Several institutional investors and hedge funds have recently modified their holdings of BVS. Nantahala Capital Management LLC grew its position in shares of Bioventus by 28.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock valued at $34,959,000 after purchasing an additional 1,155,192 shares during the period. Hillsdale Investment Management Inc. raised its holdings in shares of Bioventus by 148.7% in the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after purchasing an additional 401,230 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Bioventus in the fourth quarter valued at approximately $2,886,000. Kent Lake PR LLC acquired a new stake in shares of Bioventus in the second quarter valued at approximately $2,317,000. Finally, Kennedy Capital Management LLC raised its holdings in shares of Bioventus by 219.6% in the third quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock valued at $3,088,000 after purchasing an additional 317,157 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Price Performance

Bioventus stock opened at $8.71 on Friday. The firm has a market capitalization of $727.59 million, a P/E ratio of 21.24, a PEG ratio of 1.12 and a beta of 0.67. Bioventus has a 1 year low of $5.81 and a 1 year high of $11.25. The business has a 50-day moving average of $9.56 and a 200-day moving average of $8.67. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last posted its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.06. The company had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts anticipate that Bioventus will post 0.77 EPS for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.